ArticleDiscover oncology2025
The heterogeneous expression patterns of serum tumor markers in non-small cell lung cancer patients are predictive factors for progression-free survival.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A clinical and CT-based model for differentiating high-grade from low-grade lung adenocarcinoma in patients with idiopathic pulmonary fibrosis.American journal of translational research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeNon-small cell lung cancer (NSCLC) patients may exhibit tumor marker expression patterns that do not align with their pathological subtype, yet the clinical significance of these mismatches remains unclear. This study aims to identify novel tumor marker expression patterns and explore their relationship with tumor heterogeneity and progression-free survival (PFS) in NSCLC patients.
methodsClinical data and serum tumor marker values were collected from 142 patients with stage III-V, unresectable NSCLC in the Zhongnan Hospital of Wuhan University. The Self-organizing map algorithm was used to generate novel tumor marker patterns. We analyzed the association of these patterns with clinicopathological features and prognosis. The in vitro experiment was conducted to evaluate the impact of CA125 on the malignant behavior of squamous cell carcinoma cell lines.
resultsWe identified a pattern of low expression of SCC and high expression of CA125 in squamous cell carcinoma patients (HR 2.1704, P = 0.0304), as well as low expression of CEA and high expression of SCC in adenocarcinoma patients (HR 2.3771, P = 0.0235). Both patterns were significant predictors of poor prognosis. Furthermore, squamous cell carcinoma cell lines cultured in a high-CA125 environment exhibited accelerated proliferation in vitro.
conclusionNSCLC patients with a pattern of tumor markers mismatched to their pathological type had unfavourable PFS, suggesting a potentially higher degree of tumor heterogeneity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.